Spero Therapeutics (SPRO) Other Non Operating Income (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Other Non Operating Income came in at -$1000.0 in Q1 2026, down 200.0% YoY from $1000.0 in Q1 2025, and down 150.0% on a QoQ basis from $2000.0 in Q3 2025.
Spero Therapeutics (SPRO) Other Non Operating Income (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Other Non Operating Income data on file, last reported at -$1000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 200.0% year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5000.0 (down 93.33% YoY) and the FY2025 annual result came in at $7000.0, down 88.33% from the prior year.
- Other Non Operating Income slipped to -$1000.0 in Q1 2026, from $2000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $141000.0 in Q4 2022 to a low of -$26000.0 in Q3 2024.
- A 5-year average of $9125.0 and a median of -$1500.0 in 2023 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 3200.0% in 2024, down 600.0% in 2024.
- Tracing SPRO's Other Non Operating Income over 5 years: stood at $141000.0 in 2022, then slumped by 97.87% to $3000.0 in 2023, then soared by 3200.0% to $99000.0 in 2024, then plunged by 97.98% to $2000.0 in 2025, then slumped by 150.0% to -$1000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$1000.0 (Q1 2026), $2000.0 (Q3 2025), and $4000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -2,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | -10,000.00 |
| Mar 31, 2022 | -13,000.00 |
| Dec 31, 2021 | 521,000.00 |
| Sep 30, 2021 | -87,000.00 |
| Jun 30, 2021 | -112,000.00 |